#United States #CGM #diabetes #Twinsburg #Edgepark

Edgepark Expands Diabetes Product Lineup

Edgepark Medical Supplies has recently made significant strides in diabetes care by introducing two revolutionary products aimed at improving patient management and enhancing accessibility. As diabetes becomes increasingly prevalent in the United States, the company recognizes the urgent need for innovative solutions that meet patients' needs effectively.

New Innovations for Greater Accessibility

The Edgepark portfolio is now enriched by the introduction of the Dexcom Stelo Glucose Biosensor™ System, the first FDA-cleared over-the-counter glucose biosensor. This groundbreaking device was designed specifically for adults not on insulin and those without a history of severe hypoglycemia. Accessible via smartphone, users can obtain critical glucose data without the need for fingersticks. This technology aims to empower individuals to take charge of their metabolic health proactively.

Anthony Alvarez, Senior Vice President and General Manager at Edgepark, stated, "While CGMs have become more accessible through insurance in recent years, many still do not qualify for coverage. Over-the-counter options like the Stelo are essential for expanding access among a broader population.” Additionally, the Stelo is FSA/HSA eligible and available for order without a prescription.

Eversense® 365: Long-Lasting Monitoring Solution

In addition to the new biosensor, Edgepark has introduced the Eversense® 365 Continuous Glucose Monitoring (CGM) system. This device stands out as the first and only FDA-cleared implantable CGM designed to last an entire year. Intended for individuals aged 18 and older with Type 1 or Type 2 diabetes, the Eversense 365 offers an innovative approach to glucose monitoring. Unlike traditional CGMs that require frequent replacements, this device is inserted only once a year under the skin, significantly reducing the routine associated with continuous monitoring.

Components of the Eversense 365 CGM System

The Eversense 365 comes with several key features:
1. Implantable Sensor: A fluorescence-based sensor rests beneath the skin, minimizing the risk of dislodgement or damage.
2. Removable Smart Transmitter: This design allows users to detach and reattach the transmitter without needing a new CGM.
3. Mobile Application: An intuitive app displays real-time glucose data, allowing users greater convenience and control.

This long-wear device addresses the issue of potential “wearable fatigue” typical with frequent replacements, permitting users to focus more on their health management without the hassle of changing devices regularly.

Edgepark’s Commitment to Patient Care

As diabetes prevalence surges, Edgepark’s mission becomes ever more crucial. The company is dedicated to facilitating access to essential health solutions. With the portfolio’s enhancements like the Dexcom Stelo and Eversense 365, Edgepark aims to not only meet patients’ immediate needs but also strategically support their overall health journeys.

These innovative products reflect Edgepark's commitment to enhancing diabetes management and patient well-being. For further information about these new offerings, prospective users can explore the resources available on the Edgepark website.

Conclusion

With its latest expansions in diabetes device offerings, Edgepark is poised to play a vital role in transforming how individuals manage this chronic condition. The integration of cutting-edge technology into accessible health solutions symbolizes a positive shift in diabetes care and underscores Edgepark's dedication to meeting patients' diverse needs.